查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854540

按治療藥物、藥物類別、類型、最終用戶和分銷管道分類的老齡化黃斑部病變市場—2025-2032年全球預測

Age-related Macular Degeneration Market by Treatment, Drug Class, Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，老齡化黃斑部病變市場規模將達到 189.8 億美元，複合年成長率為 6.93%。

關鍵市場統計數據
基準年2024年 111億美元
預計年份：2025年 118.2億美元
預測年份 2032 189.8億美元
複合年成長率 (%) 6.93%

簡要概述目前影響老齡化黃斑部病變治療和策略重點的臨床、技術和商業因素。

老齡化黃斑部病變（ 老齡化 ）仍然是眼科研究和臨床診療的核心，這主要受人口結構變化和治療方法手段不斷發展的推動。 AMD的治療方法已不再局限於單一治療方法，而是擴展到生物製藥、緩釋性製劑、基因療法和先進影像技術，這給臨床醫生、支付方和藥品生產商帶來了複雜的挑戰。隨著診斷準確性的提高和病患診療流程的日益整合，相關人員必須在門診、醫院和專科中心之間協調臨床需求與實際運作。

分子生物學和藥物遞送領域的轉化醫學進展正在縮短多種治療層級的研發週期，同時也帶來了新的監管和生產挑戰。同時，支付方日益嚴格的審查和採購流程迫使醫療服務提供者最佳化治療方法和醫療服務模式。對於決策者而言，了解治療方法創新、臨床應用和供應鏈韌性之間的相互關係至關重要，這有助於制定永續的策略，在控制醫療總成本的同時，改善可衡量的治療效果。

本執行摘要整合了整體趨勢、供應鏈動態、市場區隔洞察、區域差異和策略要務，旨在為決策提供基礎。其目標是為高層領導者在當今技術創新快速發展和政策主導變革的時代，提供分析嚴謹且易於理解的基礎，幫助他們優先考慮投資、夥伴關係和營運轉型。

治療創新、診斷和數位化醫療路徑的整合如何重塑臨床實踐、商業模式和競爭優勢

老齡化黃斑部病變治療和技術的變革正在深刻地重塑臨床路徑和供應商策略。抗血管內皮生長因子（VEGF）藥物曾是新生血管疾病的標準療法，如今已與緩釋性植入物、可充電給藥平台以及旨在減輕治療負擔和提高療效持久性的新興基因治療方法並存。植入的進步，包括更高解析度的光同調斷層掃瞄和整合多模態診斷，正在增強疾病分層，並使早期干預成為可能。

人工智慧和雲端工作流程正日益廣泛地應用於轉診患者的分流、遠端監測病情進展以及跨網路標準化治療決策。這些能力正在改變醫療服務的經濟模式，將部分監測活動轉移到社區診所和遠端醫療平台，同時將手術介入集中在專科中心。真實世界證據與適應性監管路徑的融合加速了創新醫療器材和生技藥品的實用化，同時也提高了人們對核准後監測和基於療效的合約的期望。

因此，商業模式正在不斷發展，以適應基於價值的安排、緩釋性的差異化定價以及診斷供應商和治療開發商之間的新夥伴關係——這一格局共同決定了臨床療效、營運效率和競爭格局。

評估2025年美國關稅上調對眼科產品供應鏈、採購行為和策略製造決策的影響

美國2025年關稅上調計畫對眼科供應鏈和服務交付產生了連鎖的營運和戰略影響。進口零件、設備和某些生物製藥關稅的提高，增加了依賴國際製造地生產管瓶、預填充式注射器、輸液系統和專用儀器的供應商的到岸成本。為此，製造商重新評估了其籌資策略，加快了供應商多元化，並優先考慮對其他受託製造廠商進行資格認證，以降低單一國家成本衝擊的風險。

醫院和專科機構的採購團隊開始重新談判長期供應契約，並要求供應商提高價格透明度，這加大了製造商承受商業性壓力，迫使其吸收或抵消關稅相關的成本上漲。一些醫療機構考慮調整庫存管理，例如增加安全庫存和錯開採購週期，以應對短期供應中斷，但這些調整增加了營運資金和倉儲需求。同時，支付方開始更密切地審查報銷途徑和使用模式，以使報銷與整體價值相匹配，並限制關稅引發的成本上漲轉嫁到最終服務價格上。

關稅環境也引發了關於近岸外包和在地化生產能力的討論，尤其是在可以大規模生產的耗材和醫療設備領域，規模經濟效應足以抵銷資本投資。然而，監管方面的複雜性和建立國內生產前置作業時間限制了資源調配緩解成本衝擊的速度。因此，擁有靈活採購管道、對沖策略和更完善的供應商管治的公司展現出更強的韌性，而上游業務集中度高的公司則面臨更大的利潤率壓力和營運壓力。

以細分市場主導的整合洞察，將治療層級、給藥途徑、護理環境和分銷管道與臨床應用和策略機會聯繫起來。

市場細分為解讀不同治療方法和通路的臨床應用模式和機會提供了一個框架。基於治療方法的市場分析區分了非藥物干預和藥物干預，其中非藥理學的處置方法進一步細分為雷射療法和動態療法。按藥物類別分類，區分抗VEGF藥物和皮質類固醇，並將抗VEGF藥物進一步細分為阿柏西普、Bevacizumab、布羅盧西珠單抗和雷珠單抗，而將皮質類固醇藥物細分為地塞米松和曲安奈德，從而清晰地展現了治療選擇、處方動態和標籤主導的用藥情況。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 基因療法治療乾眼症和老齡化黃斑部病變的核准及上市
  • 抗 VEGF 生物相似藥可降低治療成本並擴大患者用藥範圍。
  • 開發一種緩釋性玻璃體內植入，以減少AMD患者的注射頻率
  • 將人工智慧演算法應用於老年黃斑部病變的早期診斷和進展監測。
  • 擴展遠距眼科平台，為老年黃斑部病變（AMD）管理提供遠端監測和虛擬諮詢服務
  • 對於老年人而言，個人化的營養和生活方式介入對於減緩老年性黃斑部病變的進展越來越重要。
  • 高解析度視網膜成像技術的進步可更準確地監測黃斑部病變進展

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

老齡化黃斑部病變市場

  • 非藥物療法
    • 雷射治療
    • 動態療法
  • 藥理學

老齡化黃斑部病變市場

  • 抗 VEGF
    • 阿柏西普
    • Bevacizumab
    • 布羅盧西珠單抗
    • 雷珠單抗
  • 皮質類固醇
    • 地塞米松
    • 曲安奈德

老齡化黃斑部病變市場

  • 乾燥
  • 濕的

老齡化黃斑部病變市場

  • 診所
  • 醫院
  • 專業眼科中心

老齡化黃斑部病變市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

老齡化黃斑部病變市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

老齡化黃斑部病變市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

老齡化黃斑部病變市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Regeneron Pharmaceuticals, Inc.
    • Bayer AG
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • Alcon Inc.
    • Carl Zeiss AG
    • Topcon Healthcare, Inc.
    • Nidek Co., Ltd.
    • Heidelberg Engineering GmbH
    • Optos plc
Product Code: MRR-F927BA46233D

The Age-related Macular Degeneration Market is projected to grow by USD 18.98 billion at a CAGR of 6.93% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.10 billion
Estimated Year [2025] USD 11.82 billion
Forecast Year [2032] USD 18.98 billion
CAGR (%) 6.93%

A concise orientation to current clinical, technological, and operational forces reshaping age-related macular degeneration care and strategic priorities

Age-related macular degeneration remains a central focus for ophthalmic research and clinical care, driven by demographic shifts and evolving therapeutic possibilities. The landscape has expanded beyond single-modality treatments to encompass biologics, sustained-release devices, gene-based interventions, and advanced imaging, creating a complex environment for clinicians, payers, and manufacturers to navigate. As diagnostic precision improves and patient pathways become more integrated, stakeholders must reconcile clinical need with operational realities across outpatient clinics, hospitals, and specialty centers.

Translational advances in molecular biology and drug delivery have shortened development cycles for some therapeutic classes while introducing new regulatory and manufacturing challenges. Concurrently, payer scrutiny and procurement practices have intensified, prompting providers to optimize treatment regimens and care delivery models. For decision-makers, understanding the interplay between therapeutic innovation, clinical adoption, and supply chain resiliency is essential to formulate sustainable strategies that deliver improved visual outcomes while controlling total cost of care.

This executive summary synthesizes prevailing trends, supply chain dynamics, segmentation insights, regional nuances, and strategic imperatives to enable informed action. The intent is to offer an analytically rigorous yet accessible foundation for senior leaders seeking to prioritize investments, partnerships, and operational changes in the current era of rapid technological and policy-driven shifts.

How converging therapeutic innovations, diagnostics, and digital care pathways are redefining clinical practice, commercial models, and competitive advantage

The therapeutic and technological shifts occurring in age-related macular degeneration are reshaping clinical pathways and vendor strategies in meaningful ways. Anti-VEGF agents, which once defined the standard of care for neovascular disease, now coexist with sustained-release implants, refillable delivery platforms, and emerging gene-based modalities that aim to reduce treatment burden and improve durability. Imaging advances, including higher-resolution optical coherence tomography and integrated multimodal diagnostics, have enhanced disease stratification and enabled earlier interventions.

Artificial intelligence and cloud-enabled workflows are increasingly used to triage referrals, monitor progression remotely, and standardize treatment decision-making across networks. These capabilities are altering care delivery economics by shifting some monitoring activities to community clinics and telemedicine platforms while concentrating procedural interventions within specialty centers. The convergence of real-world evidence and adaptive regulatory pathways has accelerated the translation of innovative devices and biologics, but it has also amplified expectations for post-approval surveillance and outcome-based contracting.

As a result, commercial models are evolving to accommodate value-based arrangements, differentiated pricing for sustained-delivery products, and new partnerships between diagnostic vendors and therapeutic developers. The cumulative effect is a landscape in which clinical effectiveness, operational efficiency, and commercial agility collectively determine competitive positioning.

Assessment of how 2025 tariff escalations in the United States disrupted ophthalmic supply chains, procurement behavior, and strategic manufacturing decisions

The imposition of elevated tariff measures in the United States during 2025 has created a cascade of operational and strategic consequences for the ophthalmic supply chain and service delivery. Higher duties on imported components, devices, and certain biologic inputs elevated landed costs for suppliers who rely on international manufacturing hubs for vials, prefilled syringes, delivery systems, and specialized instrumentation. In response, manufacturers reassessed sourcing strategies, accelerated supplier diversification, and prioritized qualification of alternative contract manufacturing organizations to reduce exposure to single-country cost shocks.

Procurement teams within hospitals and specialty centers began to renegotiate long-term supply agreements and to demand greater price transparency from vendors, which intensified commercial pressure on manufacturers to absorb or offset tariff-related cost increases. Some providers explored changes in inventory management, such as larger safety stocks or staggered purchasing cycles, to buffer against short-term disruption, but these adjustments increased working capital requirements and warehousing needs. In parallel, payers scrutinized reimbursement pathways and utilization patterns more closely, seeking to align reimbursement with overall value and to limit the transference of tariff-induced cost inflation to final service pricing.

The tariff environment also catalyzed conversations about nearshoring and localized production capacity, particularly for high-volume consumables and delivery devices, where scale economics could justify capital investments. Regulatory interplay and lead times for establishing domestic manufacturing, however, constrained the speed at which reshoring could mitigate cost impacts. Consequently, companies that adopted flexible sourcing, hedging strategies, and stronger supplier governance demonstrated greater resilience, while those with concentrated upstream exposure experienced amplified margin pressure and operational strain.

Integrated segmentation-driven insights linking therapeutic classes, delivery pathways, care settings, and distribution channels to clinical adoption and strategic opportunity

Segmentation provides a framework to interpret clinical adoption patterns and commercial opportunity across distinct therapeutic and distribution pathways. Based on Treatment, market analysis differentiates Non-Pharmacological modalities and Pharmacological interventions, with Non-Pharmacological approaches further situated within Laser Therapy and Photodynamic Therapy; this structure highlights where minimally invasive procedural options intersect with drug-based approaches. Based on Drug Class, the analytical lens distinguishes Anti-VEGF agents from Corticosteroids, and further dissects Anti-VEGF into Aflibercept, Bevacizumab, Brolucizumab, and Ranibizumab while categorizing Corticosteroids into Dexamethasone and Triamcinolone, enabling a clear view of therapeutic substitution, formulary dynamics, and label-driven usage.

Based on Type, the segmentation separates Dry and Wet disease pathways to emphasize differences in disease progression, unmet need, and potential for regenerative or complement-targeted strategies. Based on End User, the analysis considers Clinics, Hospitals, and Specialty Ophthalmic Centers as distinct channels of care delivery, each with unique procurement, staffing, and capacity characteristics that shape technology adoption and treatment frequency. Based on Distribution Channel, the study assesses Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy pathways to reflect evolving purchasing behaviors, the rise of digital dispensing models, and implications for cold-chain logistics and patient access.

Together, these segmentation dimensions allow for nuanced interpretation of clinical utilization patterns, capital and operating investment priorities, and the differential impact of policy or reimbursement changes across care settings. By mapping therapeutic innovations to end-user and distribution realities, stakeholders can better anticipate adoption bottlenecks and prioritize interventions that address the most consequential frictions.

Regional nuances in clinical adoption, regulatory pathways, and commercialization approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics continue to shape clinical practice patterns, regulatory expectations, and commercialization strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established reimbursement systems and high adoption rates of intravitreal therapies have driven an emphasis on treatment optimization, adherence strategies, and innovations that reduce visit frequency; provider consolidation and integrated delivery networks have also influenced procurement and contracting behavior. Across Europe, Middle East & Africa, heterogeneous regulatory pathways and payer models have led manufacturers to pursue localized evidence generation and adaptive pricing arrangements to secure formulary inclusion and maintain profitability.

In the Asia-Pacific region, rapid investment in diagnostic infrastructure, growing clinical trial activity, and increasing demand from aging populations have accelerated uptake of next-generation therapeutics, while a focus on manufacturing scale and cost optimization has made the region central to global supply networks. Cross-region collaboration, such as multinational clinical programs and harmonized regulatory submissions, has become more common as developers seek to shorten time-to-market and align safety monitoring across jurisdictions. Variations in healthcare infrastructure and provider distribution also affect where procedural capacity is concentrated, often requiring differentiated commercial and training strategies for specialty centers versus community clinics.

Understanding these regional nuances is critical for designing phased market entry plans, aligning regulatory dossiers with local evidence needs, and developing channel strategies that reflect payer expectations and provider capabilities within each geography.

Strategic corporate behaviors and partnership models shaping therapeutic leadership, delivery innovations, and integrated offerings in the AMD ecosystem

Corporate strategy in the age-related macular degeneration ecosystem is characterized by a mix of portfolio diversification, targeted partnerships, and investments in advanced manufacturing and data capabilities. Established biopharmaceutical sponsors maintain leadership through iterative improvements to licensed anti-VEGF agents and by sponsoring real-world evidence studies to support label expansions and dosing innovations. Simultaneously, companies with niche capabilities in sustained-delivery systems and ocular devices are leveraging strategic alliances to combine delivery platforms with established biologics, creating differentiated offerings that address clinician and patient demand for reduced treatment burden.

Across the competitive landscape, alliances between therapeutic developers, contract manufacturers, and diagnostic vendors have increased, reflecting a recognition that integrated solutions-combining therapy, monitoring, and adherence tools-provide stronger commercial value propositions. Investment activity has favored firms that can demonstrate scalable aseptic manufacturing, robust cold-chain logistics, and regulatory experience in ophthalmic modalities. Additionally, firms pursuing novel mechanisms for geographic atrophy and complement inhibition have attracted attention from investors and partners, underscoring the broader appetite for first-in-class interventions within dry AMD.

Companies that prioritize interoperable data strategies, regulatory planning for global submissions, and flexible commercial models for diverse payer environments are better positioned to capture opportunities. At the same time, market entrants must navigate pricing scrutiny and evidentiary expectations, making strategic collaborations and selective evidence generation crucial to commercial success.

Practical and prioritized strategic actions executives should implement to strengthen clinical value, supply resilience, market access, and commercial differentiation

Industry leaders should pursue a set of pragmatic actions to align clinical value with commercial sustainability and operational resilience. First, prioritize development of durable delivery mechanisms and combination approaches that demonstrably reduce treatment frequency while preserving or enhancing long-term visual outcomes; evidence packages should emphasize patient-centric endpoints and health system resource utilization. Second, strengthen supply chain flexibility by qualifying multiple manufacturing partners across geographies and by investing in inventory analytics that reduce lead-time risk while controlling working capital demands.

Third, implement differentiated market access strategies that tailor evidence generation to regional payer expectations and to the specific needs of clinics, hospitals, and specialty centers. This includes negotiation-ready value propositions that reflect real-world treatment pathways and potential savings from reduced visit burden. Fourth, embed digital and diagnostic partnerships into commercial plans to support remote monitoring, adherence programs, and outcome tracking, thereby improving post-launch data collection and enabling outcome-based contracting where feasible. Fifth, foster cross-functional alignment between regulatory, clinical, and commercial teams to streamline global submissions and coordinate post-approval safety monitoring, which will accelerate adoption while maintaining compliance.

Taken together, these actions reduce operational exposure, enhance provider and patient value, and create defensible differentiation in a competitive therapeutic landscape. Executives should sequence investments to balance near-term revenue protection with mid- to long-term capability building that supports sustained leadership.

A robust mixed-methods research framework integrating primary stakeholder interviews, secondary regulatory and clinical evidence, and scenario validation for actionable intelligence

The research approach combined primary qualitative inquiry with comprehensive secondary evidence review to ensure robustness and practical relevance. Primary research included structured interviews with ophthalmologists, procurement leads in hospitals and specialty centers, senior commercial executives, and clinical trial investigators to capture frontline perspectives on treatment adoption, operational constraints, and payer interactions. Secondary sources encompassed peer-reviewed clinical literature, regulatory approval documents, clinical trial registries, and public filings to validate therapeutic profiles, indications, and safety data.

Data synthesis involved cross-validation of interview insights with published evidence and regulatory summaries, supplemented by scenario analysis to explore operational and policy contingencies such as tariff changes or shifts in reimbursement. Segmentation frameworks were developed by mapping therapeutic modalities, drug classes, disease subtypes, end-user settings, and distribution channels to clinical workflows and procurement pathways. Quality assurance measures included reconciliation of conflicting sources, iterative expert review, and transparent documentation of assumptions and inclusion criteria.

Limitations of the methodology include variability in regional reporting standards and the evolving nature of clinical trial outcomes, which necessitates ongoing monitoring of late-stage data. Nonetheless, the triangulated approach provides a reliable foundation for strategic decision-making by integrating real-world clinician perspectives with rigorous secondary evidence and disciplined analytical techniques.

Concluding synthesis linking clinical innovation, operational preparedness, and strategic imperatives required to realize improved outcomes in age-related macular degeneration

In sum, the age-related macular degeneration landscape is at an inflection point where therapeutic innovation, delivery technologies, and systemic pressures intersect to reshape care paradigms. Advances that reduce treatment frequency or address unmet needs in dry AMD offer meaningful clinical promise, but their realization depends on coordinated evidence generation, adaptive commercial models, and resilient supply chains. Stakeholders who proactively adapt procurement practices, invest in manufacturing agility, and align evidence strategies with payer expectations will be better equipped to translate scientific breakthroughs into sustainable clinical and commercial value.

Operationally, the capacity to integrate diagnostics, digital monitoring, and adherence solutions into product offerings will influence adoption trajectories and payer receptivity. Strategically, selective partnerships and targeted regional approaches enable sponsors to balance the demands of regulatory heterogeneity and localized payer systems. As the landscape continues to evolve, ongoing vigilance, flexible planning, and a focus on measurable patient benefit will be essential to converting innovation into improved outcomes across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Approval and market adoption of gene therapy approaches for dry age-related macular degeneration
  • 5.2. Emergence of anti-VEGF biosimilars reducing treatment costs and expanding patient access
  • 5.3. Development of sustained-release intravitreal implants to reduce injection frequency in AMD patients
  • 5.4. Integration of artificial intelligence algorithms for early diagnosis and progression monitoring of AMD
  • 5.5. Expansion of teleophthalmology platforms to deliver remote monitoring and virtual consultations for AMD management
  • 5.6. Growing emphasis on personalized nutrition and lifestyle interventions to slow AMD progression in aging populations
  • 5.7. Advancements in high-resolution retinal imaging devices for more precise monitoring of macular degeneration progression

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Age-related Macular Degeneration Market, by Treatment

  • 8.1. Non-Pharmacological
    • 8.1.1. Laser Therapy
    • 8.1.2. Photodynamic Therapy
  • 8.2. Pharmacological

9. Age-related Macular Degeneration Market, by Drug Class

  • 9.1. Anti-Vegf
    • 9.1.1. Aflibercept
    • 9.1.2. Bevacizumab
    • 9.1.3. Brolucizumab
    • 9.1.4. Ranibizumab
  • 9.2. Corticosteroid
    • 9.2.1. Dexamethasone
    • 9.2.2. Triamcinolone

10. Age-related Macular Degeneration Market, by Type

  • 10.1. Dry
  • 10.2. Wet

11. Age-related Macular Degeneration Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Specialty Ophthalmic Centers

12. Age-related Macular Degeneration Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Age-related Macular Degeneration Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Age-related Macular Degeneration Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Age-related Macular Degeneration Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Regeneron Pharmaceuticals, Inc.
    • 16.3.2. Bayer AG
    • 16.3.3. Novartis AG
    • 16.3.4. F. Hoffmann-La Roche AG
    • 16.3.5. Alcon Inc.
    • 16.3.6. Carl Zeiss AG
    • 16.3.7. Topcon Healthcare, Inc.
    • 16.3.8. Nidek Co., Ltd.
    • 16.3.9. Heidelberg Engineering GmbH
    • 16.3.10. Optos plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMA